Ivivi PEMF Technology Provides a Non-Pharmacologic Approach for AHA Guidelines to Avoid NSAIDs for Patients at Risk for Heart Di
22 Março 2007 - 9:00AM
Business Wire
Ivivi Technologies, Inc. (AMEX:II), an innovator of non-invasive,
electrotherapeutic technology, today commented on the recent
American Heart Association�s (AHA) Scientific Statement, published
in Circulation: Journal of the American Heart Association,
recommending that due to increased risk of heart attack and stroke,
physicians should avoid prescribing non-steroidal anti-inflammatory
drugs (NSAIDs) to patients at risk for, or with, heart disease,
unless other non-pharmacological treatments have failed to produce
the desired clinical result. Andre� DiMino, Vice Chairman and
Co-Chief Executive Officer, stated, �AHA�s guideline should serve
as a �call to action� for physicians and the medical community,
encouraging further exploration of the benefits of
non-pharmacological therapies to reduce chronic pain. We intend to
initiate a working relationship with the AHA to ensure that its
member physicians and other healthcare professionals are aware of
the benefits of Ivivi�s Electroceuticals� and how they could be
useful in light of the AHA�s guideline to use non-pharmacological
therapies whenever possible.� Great strides have been made over the
past several years in elucidating the mechanisms of action of
pulsed electromagnetic field, or PEMF. This technology, which
creates non-thermal electrical current in injured soft tissue, is
specifically configured to augment the biochemical and
physiological processes used by the human body to reduce pain and
edema in its natural quest for tissue repair. The Company�s
proprietary PEMF signals, which are referred to as
Electroceuticals�, are delivered by devices which have been cleared
by the U.S. Food and Drug Administration (FDA) for the treatment of
post-operative pain and edema in soft tissue. These devices have
been used in over 600,000 non-invasive applications for the
treatment of pain and edema following plastic and reconstructive
surgery and chronic inflammatory disorders, including chronic
wounds. The therapy is non-toxic and has no known side effects.
�The positive benefits of electromagnetic modulation of the body�s
own electrochemical physiology have been demonstrated in animal and
human clinical studies for the treatment of recalcitrant fractures
and chronic wounds. PEMF efficacy has also been demonstrated for
increased growth of blood vessels and reduction of pain and
swelling after surgical procedures, and shows great promise as an
alternative to NSAIDs for the relief of chronic and acute pain,�
said Dr. Arthur A. Pilla, Professor of Biomedical Engineering,
Columbia University, Science Director and Chairman of the
Scientific Advisory Board, Ivivi Technologies, Inc., and inventor
of the first PEMF bone growth stimulator which was FDA-cleared for
recalcitrant fracture repair. �Ivivi believes the world of medicine
is on the verge of exploiting the relationship between the body�s
electrochemistry and healing. Electrotherapeutics has been shown to
be inherently safer than many drugs, which Ivivi believes creates a
natural advantage for patients, healthcare professionals and even
insurers. Certainly, the use of PEMF technology in orthopedics has
resulted in significant reductions in morbidity and the cost of
health care for these indications since 1980.� In its Scientific
Statement, the AHA has specifically stated that some NSAIDs,
including ibuprofen and cox2 inhibitors, increase the risk of heart
failure, stroke, hypertension and gastrointestinal bleeding in some
patients. Additional information on the AHA Scientific Statement
can be found at
http://www.americanheart.org/presenter.jhtml?identifier=3045689.
About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi
Technologies, Inc. is a medical technology company focusing on
designing, developing and commercializing its proprietary
electrotherapeutic technology platform. Ivivi�s research and
development activities are focused specifically on pulsed
electromagnetic field, or PEMF, technology, which, by creating a
therapeutic electrical current in injured soft tissue, stimulates
biochemical and physiological healing processes to help repair the
injured tissue and reduce related pain and inflammation. The
Company�s Electroceuticals� have been used in non-invasive
treatments for a wide array of conditions, including chronic
wounds, pain and edema following plastic and reconstructive surgery
and chronic inflammatory disorders. Forward-Looking Statements This
release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements reflect management's
current knowledge, assumptions, judgment and expectations regarding
future performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct and
you should be aware that actual results could differ materially
from those contained in the forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, including, but not limited to, the Company�s limited
operating history, history of significant and continued operating
losses and substantial accumulated earnings deficit, difficulties
with its financial accounting controls, the failure of the market
for the Company�s products to continue to develop, the inability
for customers to receive third party reimbursement, the inability
to obtain additional capital, the inability to protect the
Company�s intellectual property, the loss of any executive officers
or key personnel or consultants, competition, changes in the
regulatory landscape or the imposition of regulations that affect
the Company�s products and other risks detailed from time to time
in the Company�s filings with the Securities and Exchange
Commission, including the Company�s registration statement on Form
SB-2. The Company assumes no obligation to update the information
contained in this press release.
Equifin (AMEX:II)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Equifin (AMEX:II)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024